MetaCap

Evommune (EVMN) vs Relmada Therapeutics (RLMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Relmada Therapeutics (RLMD) has outperformed Evommune (EVMN) over the past year, losing 38.6% versus a loss of 62.4%. Evommune is the larger company by market cap ($291.1 million vs $279.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

EVMN-62.37%RLMD-38.64%
+92%+6%-81%
Nov 21, 20251 yearNov 20, 2026
EVMN-61.76%RLMD-1.13%
+201%+58%-85%
Nov 3, 20255 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

EVMN versus RLMD key metrics
MetricEVMNRLMD
Share price$7.04$2.62
Market cap$291.10M$279.54M
1-day change-2.76%-15.76%
YTD return-58.88%-45.76%
1-year return-62.37%-38.64%
5-year return—-86.09%
EPS (TTM)$-3.83$-0.73
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$13.00M—
Revenue growth (YoY)+85.71%—
Net income (latest FY)$-68.87M$-57.39M
Operating margin-623.62%—
Net margin-529.77%—
52-week high$33.20$8.00
52-week low$4.94$2.60
Distance from 52-week high-78.80%-67.25%
Analyst consensusbuystrong_buy
Avg. price target upside+210.94%+310.31%
Average volume841.65K1.45M
Shares outstanding41.35M106.69M
Employees4817
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • RLMD has outperformed EVMN by 23.7 percentage points over the past year.

About Evommune

EVMN stock →

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 48 employees

About Relmada Therapeutics

RLMD stock →

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States.

Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees

EVMN vs RLMD FAQ

Which is bigger, Evommune or Relmada Therapeutics?

Evommune (EVMN) is larger, with a market capitalization of $291.10M compared with $279.54M for Relmada Therapeutics (RLMD).

Which stock has performed better over the past year, EVMN or RLMD?

RLMD returned -38.64% over the past 12 months, compared with -62.37% for EVMN (price return, excluding dividends). Past performance does not predict future results.

Are Evommune and Relmada Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons